A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x
CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or
Intermediate-2/High Risk Myelodysplastic Syndrome